Extramedullary haematopoiesis correlates with genotype and absence of cardiac iron overload in polytransfused adults with thalassaemia
- PMID: 24120603
- PMCID: PMC3934250
- DOI: 10.2450/2013.0287-12
Extramedullary haematopoiesis correlates with genotype and absence of cardiac iron overload in polytransfused adults with thalassaemia
Abstract
Background: The mechanisms responsible for the sporadic occurrence of extramedullary haematopoiesis in polytransfused thalassaemic patients have not yet been clarified. In this study we tried to elucidate the influence of genotype and other factors on the presence of extramedullary haematopoiesis.
Materials and methods: We performed a retrospective database review of our polytransfused thalassaemic patients between January 2006 and December 2011. Demographic, transfusional, genetic, radiological and biochemical data were collected and statistically analysed.
Results: Extramedullary haematopoiesis was found in 18 out of 67 patients (27%). All of them were splenectomised, had a higher nucleated red blood cell count and higher levels of the soluble form of transferrin receptor with respect to patients without extramedullary haematopoiesis; furthermore, patients with EMH had a lower transfusional iron intake and a higher pre-transfusion haemoglobin level as compared with those without extramedullary haematopoiesis. Ten out of the 18 patients with extramedullary haematopoiesis were compound heterozygotes for IVS 1-6/codon 39. A high frequency of thrombotic events was also recorded among all patients followed at our centre with this genetic profile.
Discussion: Among our cohort of thalassaemic polytransfused patients, extramedullary haematopoiesis was not such a rare event. Furthermore, we identified a group of patients, most of whom were compound heterozygotes for IVS 1-6/codon 39, with increased soluble transferrin receptor levels and excessive expansion of erythroid marrow probably responsible for the tendency to develop extramedullary haematopoiesis.
Figures
References
-
- Taher A, Isma’eel H, Cappellini MD. Thalassaemia intermedia: revisited. Blood Cells Mol Dis. 2006;37:12–20. - PubMed
-
- Logothetics J, Constantoulakis M, Exonomidou J, et al. Thalassaemia major (homozygous beta thalassemia). A survery of 138 cases with emphasis on neurologic and muscular aspects. Neurology. 1972;22:249–304. - PubMed
-
- Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115:1886–92. - PubMed
-
- Cazzola M, De Stefano P, Ponchio L, et al. Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. Br J Haematol. 1995;89:473–8. - PubMed
-
- Tancabelic J, Sheth S, Paik M, Piomelli S. Serum transferrin receptor as a marker of erythropoiesis suppression in patients on chronic transfusion. Am J Hematol. 1999;60:121–5. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources